NYSE:PRX - Par Pharmaceutical Companies Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Par Pharmaceutical Companies, Inc. is a holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc., is in the business of developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States. The Company operates primarily in the United States as two business segments: Par Pharmaceutical (Par), its generic products division, and Strativa Pharmaceuticals (Strativa), its branded products division. In February 17, 2012, the Company acquired Edict Pharmaceuticals Private Limited. On November 17, 2011, it acquired Anchen Incorporated and its subsidiary, Anchen Pharmaceuticals, Inc. In October 2011, it acquired rights to three products from Teva Pharmaceuticals in connection with Teva's acquisition of Cephalon. In September 2012, certain affiliates of TPG acquired the Company.

Receive PRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A



Sales & Book Value

Annual SalesN/A



OptionableNot Optionable

Par Pharmaceutical Companies (NYSE:PRX) Frequently Asked Questions

What is Par Pharmaceutical Companies' stock symbol?

Par Pharmaceutical Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRX."

Has Par Pharmaceutical Companies been receiving favorable news coverage?

News coverage about PRX stock has been trending somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Par Pharmaceutical Companies earned a coverage optimism score of 1.5 on InfoTrie's scale. They also assigned media stories about the healthcare company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Par Pharmaceutical Companies' key executives?

Par Pharmaceutical Companies' management team includes the folowing people:
  • Paul V. Campanelli, Chief Executive Officer (Age 54)
  • Michael A. Tropiano, Chief Financial Officer, Executive Vice President (Age 57)
  • Terrance John Coughlin, Chief Operating Officer (Age 52)
  • Thomas J. Haughey, Chief Administrative Officer, General Counsel (Age 51)

How do I buy shares of Par Pharmaceutical Companies?

Shares of PRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Par Pharmaceutical Companies' official website?

The official website for Par Pharmaceutical Companies is http://www.parpharm.com/.

How can I contact Par Pharmaceutical Companies?

Par Pharmaceutical Companies' mailing address is 1 Ram Ridge Rd, CHESTNUT RIDGE, NY 10977-6714, United States. The healthcare company can be reached via phone at +1-845-5735500.

MarketBeat Community Rating for Par Pharmaceutical Companies (NYSE PRX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  97 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  183
MarketBeat's community ratings are surveys of what our community members think about Par Pharmaceutical Companies and other stocks. Vote "Outperform" if you believe PRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel